Avidity Biosciences CEO expects ‘lots of rumors’ about acquisition interest

Sarah Boyce, President and CEO of Avidity Biosciences (RNA), stated earlier while presenting at the Cantor Global Healthcare Conference in response to a question about rumors of acquisition interest in the company: “I would say we’re now entering into an era, another Taylor Swift pun, we’re now entering into an era where we’re probably gonna have a lot of rumors about us and around interests in Avidity. Like, we have three drugs that we’re looking to launch in a twelve month period. Two of those drugs, we believe are multi billion dollar indications. So extremely valuable, and I expect, you know, there’s gonna be lots of rumors about us. What I will say is for us as a team, we’re a 100% focused on delivering to patients and getting our drugs to patients as quickly as possible because we believe, yeah, as does the patient community, the clinical community, and I I think starting the investor community now as well, and I know you’re a big supporter, Eric, that we have the potential to make a profound impact in tens of thousands of people’s lives, and that’s what we’re focused on.”